Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (familiar brand names include Jardiance, Farxiga, Ozempic, Wegovy, Mounjaro, Zepbound, Victoza ) are increasingly popular options, not only for glycemic control among patients with diabetes, but also for heart failure management and weight losseven in non-diabetics
FRET between FITC-agonist and terbium-labeled internalized SNAP-GLP-1R was measured as above
Both medications can also cause less common but more serious issues, such as pancreatitis
Diarrhea occurs in approximately 30% of patients taking semaglutide 2.4 mg (Wegovy) and 19-23% of patients taking tirzepatide (Zepbound) according to FDA prescribing information
Those medical conditions arent stigmatized like obesity has been for decades
Proper refrigeration slows the degradation of sensitive peptide compounds